This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow | MicrobiomeTrials
← Back to trials NCT03363373
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2018-04-03Est. Completion: 2026-06
Enrollment target: 122 participantsLocations Riley Hospital for Children, Indianapolis, Indiana, United States Memorial Sloan Kettering Cancer Center, New York, New York, United States The Hospital for Sick Children, Toronto, Canada Rigshospitalet, Copenhagen, Denmark University Medical Center Hamburg-Eppendorf, Hamburg, Germany Johannes Gutenberg-Universität, Mainz, Germany University Hospital Regensburg, Regensburg, Germany Hong Kong Children's Hospital, Hong Kong, Hong Kong Queen Mary Hospital, Hong Kong, Hong Kong Tata Memorial Centre, Mumbai, India Giannina Gaslini Hospital, Genoa, Genoa, Italy Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Milan, Italy Ospedale Pediatrico Bambino Gesù, Rome, Italy Hospital Sant Joan de Déu, Barcelona, Spain Hospital Infantil Universitario Niño Jesús, Madrid, Spain Hospital Universitario Virgen Del Rocío, Seville, Spain Hospital Universitario y Politécnico La Fe, Valencia, Spain The Royal Glasgow Children's Hospital, Glasgow, United Kingdom Other microbiome trials you might be interested in Refractory Solid Tumors Relapsed Solid Tumors Relapsed Neuroblastoma Refractory Neuroblastoma Relapsed Rhabdomyosarcoma Refractory Rhabdomyosarcoma
The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agen…
Los Angeles, United States Est. completion Apr 2030
Neuroendocrine Carcinomas Neuroendocrine Tumors
Leeds General Infirmary, Leeds, United Kingdom
University Hospital Southampton, Southampton, United Kingdom Carcinoma, Neuroendocrine
Carcinoma, Adrenocortical
Carcinoma, Adrenal Cortical
Background:
Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal gl…
Bethesda, United States Est. completion Oct 30, 2027